ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

In Brief: NCI Holds Paylines To 160, 165 for Now While Anticipating Another OMB Rescission Request

November 14, 1986

NCCN Launches Outcomes Improvement Program

August 12, 2011

Atlas Showing County Cancer Rates Available

July 18, 1975

Fisher Says Forget Grants-Contract Argument; What’s Needed Is More Flexibility

April 13, 1979

Melanoma Vaccine Near Phase 3, Other Studies Discussed At ACS Seminar

April 13, 1990

Powers, NCI Still Disagree On Organ Systems Provisions

April 22, 1983